Multiple Myeloma

The FDA approved a teclistamab combination in relapsed/refractory myeloma, Pylarify TruVu for PSMA-PET imaging in prostate cancer, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the significance of the FDA approval of daratumumab plus VRd for the treatment of newly diagnosed, transplant-ineligible multiple myeloma.

The FDA has approved teclistamab plus daratumumab for relapsed/refractory multiple myeloma after at least 1 prior line of therapy.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

In an OncLive Ask the Expert program, Sagar Lonial, MD, FACP, FASCO, outlined how CELMoDs may be integrated into multiple myeloma care.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

The FDA accepted an NDA for iberdomide plus daratumumab/dexamethasone in relapsed/refractory multiple myeloma, supported by MRD benefit in EXCALIBER-RRMM.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Experts break down the FDA’s draft guidance on the use of MRD end points to support accelerated drug approvals in multiple myeloma.

CARTITUDE-4 data show heterogeneous outcomes with cilta-cel after progression on bridging therapy in relapsed/refractory multiple myeloma.

Kenneth Jin Chang Lim, MBBS, discusses the failure of dexamethasone to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy.

Cilta-cel was linked with low progression events and a potential cure fraction in relapsed/refractory multiple myeloma.

A real-world cilta-cel study revealed a link between high lymphocyte peaks and failed bridging to parkinsonism and nonrelapse mortality, potentially guiding early intervention.

Sagar Lonial, MD, FACP, FASCO, discusses the potential role of CELMoD-based combination approaches in newly diagnosed, transplant-ineligible multiple myeloma.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

The American Cancer Society has released their annual Cancer Facts & Figures and Cancer Statistics reports.

Rahul Banerjee, MD, FACP, discusses the potential long-term role of CELMoDs in the multiple myeloma treatment paradigm.

Marc J. Braunstein, MD, PhD, details the significance of the FDA approval of daratumumab plus VRd in transplant-ineligible, newly diagnosed myeloma.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

Sikander Ailawadhi, MD, and Beth Faiman, CNP, PhD, discuss the ongoing development of subcutaneous isatuximab administration via an on-body injector for patients with multiple myeloma.

IBI3003 received fast track designation from the regulatory agency in the setting of relapsed/refractory multiple myeloma.

Andrew Yee, MD, and Krina Patel, MD, MSc, discuss up-and-coming oral PI combination regimens in relapsed/refractory multiple myeloma.